BioCorRx Inc. (BICX)
| Previous Close | 0.0000 |
| Open | 0.3000 |
| Bid | 0.3000 x 0 |
| Ask | 0.4995 x 0 |
| Day's Range | 0.3000 - 0.3000 |
| 52 Week Range | 0.2820 - 1.6100 |
| Volume | |
| Avg. Volume | 667 |
| Market Cap | 3.267M |
| Beta (5Y Monthly) | 0.62 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4800 |
| Earnings Date | Aug 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireBioCorRx Reports Business Update for the Second Quarter of 2024
ANAHEIM, CA, Aug. 15, 2024 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the three months ended June 30, 2024, and reported on recent corporate developments. Additionally, BioCorRx Inc. announces the expansion of its intellectual property portfolio with a new international patent awarded from Israel for the treatment of weight loss. This pat
NewMediaWireBioCorRx Reports Business Update for the First Quarter of 2024
ANAHEIM, CA - (NewMediaWire) - May 16, 2024 - BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the three months ende...
